PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
News|Videos|October 18, 2024
AAPS PharmSci 360 2024: How AI is Helping to Ensure Companies’ GMP Health
Author(s)Patrick Lavery
Redica Systems has been assisting pharmaceutical companies in determining GMP quality risks at their manufacturing sites, and with AI, it has a relatively new addition to its toolbox.
Advertisement
As part of its AAPS PharmSci 360 2024 coverage, Pharmaceutical Technology® interviewed Jerry Chapman, senior good manufacturing practice (GMP) quality expert with Redica Systems, about his presentation at the conference, “Using AI to Evaluate GMP Health of Drug Manufacturing Sites,” to be delivered on Tuesday, Oct. 22, 2024. Chapman discussed the importance of determining GMP quality risks for any company, and how artificial intelligence (AI) is now assisting Redica in facilitating these evaluations.
“What we have done is, we've built something called an ontology, and the ontology is really, for lack of a better analogy, it’s like a dictionary of terms and what they mean with our industry,” Chapman says in the interview. “So, if you went to ChatGPT and asked it about an API, it would think you were talking about an application program interface. In the ... wide world, if you will, that that's what people would equate that to. In the pharmaceutical industry, it is an active pharmaceutical ingredient, right? So, we have to spend a fair amount of time training the AI on our ontology and being able to train it so that it can recognize those terms and be able to ferret them out in inspection documents.”
Click the above video to watch the full interview.
Chapman’s presentation will be at 10:30 a.m. MT on the 22nd, in Room 155E. AAPS PharmSci 360 is being held from Oct. 20–23, 2024 in Salt Lake City, Utah.
Advertisement
Related to this article
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
Silvia Forroova, director of Partnerships & Sustainability at CPHI, and founder of the CPHI Sustainability Collective, provides a preview of the new Sustainability Summit at CPHI Milan 2026.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss navigating CMC requirements for new modalities and AI’s involvement in CMC.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discussed how CMC review practices are evolving and what that means for manufacturing strategy.
Advertisement
Advertisement